title: Analgesic and anti-inflammatory activities of a fraction rich in oncocalyxone A isolated from Auxemma oncocalyx.
abstract: In the present work we studied the antinociceptive and antiedematogenic effects of a quinone fraction (QF) isolated from the heartwood of Auxemma oncocalyx Taub. The major constituent of QF, which represented around 80% of this fraction, was a terpenoid quinone named oncocalyxone A (1). Results show that QF (10 and 30 mg/kg body wt., i.p.) significantly inhibited paw edema induced by carrageenan at the second, third, and fourth hours. The effect was dose-dependent and long lasting, and QF was less effective orally. An antiedematogenic effect was also demonstrated in the dextran-induced paw edema. In this model, however, QF was somewhat less potent. QF (1 and 5 mg/kg body wt., i.p.) inhibited acetic acid-induced abdominal contractions in mice in a dose-dependent manner. In addition, QF (5 and 10 mg/kg body wt., i.p.) inhibited only the second phase (inflammatory) in the formalin test, and showed no effect in the hot-plate test in mice. The antinociceptive activity of QF was predominantly peripheral and independent of the opioid system. The observed effects of QF are, at least in part, probably due to the presence of oncocalyxone A (1).
authors.affiliation: Departamento de Farmácia, Universidade Federal do Ceará, Fortaleza, Ce, Brasil.
authors.forename: M A D
authors.initials: MA
authors.lastname: Ferreira
authors.forename: Osmar D R H
authors.initials: OD
authors.lastname: Nunes
authors.forename: Juvenia B
authors.initials: JB
authors.lastname: Fontenele
authors.forename: Otília D L
authors.initials: OD
authors.lastname: Pessoa
authors.forename: Telma L G
authors.initials: TL
authors.lastname: Lemos
authors.forename: Glauce S B
authors.initials: GS
authors.lastname: Viana
mesh_terms: D019342:Acetic Acid; D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000880:Anthraquinones / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D028082:Boraginaceae; D002351:Carrageenan; D004305:Dose-Response Relationship, Drug; D004487:Edema / Q000139:chemically induced / Q000517:prevention & control*; D005557:Formaldehyde; D007274:Injections, Intraperitoneal; D008297:Male; D010146:Pain / Q000139:chemically induced / Q000517:prevention & control*; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar
chemical_list: D018712:Analgesics, Non-Narcotic; D000880:Anthraquinones; D000893:Anti-Inflammatory Agents; D010936:Plant Extracts; C408504:oncocalyxone A; D005557:Formaldehyde; D002351:Carrageenan; D019342:Acetic Acid